Replimune Group (NASDAQ:REPL) Shares Up 7.2% – Should You Buy?

Replimune Group, Inc. (NASDAQ:REPL) rose 7.2% during trading on Thursday . The company traded as high as $8.15 and last traded at $8.1590. Approximately 186,713 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 1,416,083 shares. The stock had previously closed at $7.61.

Analyst Ratings Changes

Several equities research analysts recently weighed in on REPL shares. Piper Sandler upped their price objective on shares of Replimune Group from $13.00 to $14.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Wedbush raised their target price on shares of Replimune Group from $18.00 to $19.00 and gave the company an “outperform” rating in a report on Wednesday, February 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Replimune Group in a research report on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Replimune Group presently has an average rating of “Hold” and a consensus target price of $10.00.

Replimune Group Price Performance

The business’s 50-day simple moving average is $7.57 and its two-hundred day simple moving average is $7.80. The stock has a market cap of $645.23 million, a price-to-earnings ratio of -2.27 and a beta of 0.72. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.08. Research analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Hedge Funds Weigh In On Replimune Group

Several large investors have recently bought and sold shares of REPL. International Assets Investment Management LLC acquired a new stake in shares of Replimune Group during the fourth quarter valued at about $29,000. CWM LLC raised its holdings in Replimune Group by 248.6% in the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after buying an additional 2,886 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in Replimune Group by 37.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after buying an additional 1,879 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Replimune Group during the 2nd quarter worth approximately $69,000. Finally, Russell Investments Group Ltd. boosted its position in Replimune Group by 3,638.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after buying an additional 7,569 shares during the period. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.